GI-102 is under clinical development by GI Innovation and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success rate (PTSR) ...
The games for Gi-hun will end with the forthcoming third season, but Hwang Dong-hyuk has shared his thoughts with THR on how the series could expand into a franchise.